Correlation Between Edgewise Therapeutics and Akero Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Edgewise Therapeutics and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Edgewise Therapeutics and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Edgewise Therapeutics and Akero Therapeutics, you can compare the effects of market volatilities on Edgewise Therapeutics and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Edgewise Therapeutics with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Edgewise Therapeutics and Akero Therapeutics.

Diversification Opportunities for Edgewise Therapeutics and Akero Therapeutics

-0.16
  Correlation Coefficient

Good diversification

The 3 months correlation between Edgewise and Akero is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Edgewise Therapeutics and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Edgewise Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Edgewise Therapeutics are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Edgewise Therapeutics i.e., Edgewise Therapeutics and Akero Therapeutics go up and down completely randomly.

Pair Corralation between Edgewise Therapeutics and Akero Therapeutics

Given the investment horizon of 90 days Edgewise Therapeutics is expected to under-perform the Akero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Edgewise Therapeutics is 3.59 times less risky than Akero Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Akero Therapeutics is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  2,796  in Akero Therapeutics on December 29, 2024 and sell it today you would earn a total of  1,562  from holding Akero Therapeutics or generate 55.87% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Edgewise Therapeutics  vs.  Akero Therapeutics

 Performance 
       Timeline  
Edgewise Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Edgewise Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Akero Therapeutics 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Edgewise Therapeutics and Akero Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Edgewise Therapeutics and Akero Therapeutics

The main advantage of trading using opposite Edgewise Therapeutics and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Edgewise Therapeutics position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.
The idea behind Edgewise Therapeutics and Akero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance